DOCSLIB.ORG

A Dissertation on CYTOLOGIC SPECTRUM of SALIVARY GLAND

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

A Dissertation on CYTOLOGIC SPECTRUM OF SALIVARY GLAND LESIONS WITH HISTOPATHOLOGICAL CORRELATION Dissertation submitted to THE TAMILNADU Dr.M.G.R MEDICAL UNIVERSITY CHENNAI-600032 In Partial fulfillment of the regulations Required for the award of M.D.Degree in PATHOLOGY (BRANCH III) DEPARTMENT OF PATHOLOGY COIMBATORE MEDICAL COLLEGE MAY 2020 UNIVERSITY REGISTRATION NO: 201713251 DECLARATION I solemnly declare that the dissertation titled “CYTOLOGIC SPECTRUM OF SALIVARY GLAND LESIONS WITH HISTOPATHOLOGICAL CORRELATION” was done by me at Coimbatore Medical College, during the period 2018 -2019 under the guidance and supervision of Prof.A.DHANALAKSHMI, MD., to be submitted to The Tamilnadu Dr.M.G.R.Medical University towards the partial fulfilment of requirements for the award of MD DEGREE in PATHOLOGY BRANCH –III. Place : Coimbatore Date :22.10.2019 Dr.T.ANITHA, Post Graduate Student, Department of Pathology, Coimbatore Medical College. CERTIFICATE I This to certify that the dissertation entitled “CYTOLOGIC SPECTRUM OF SALIVARY GLAND LESIONS WITH HISTOPATHOLOGICAL CORRELATION” is a record of bonafide work done by Dr. T.ANITHA, Post Graduate Student in the Department of Pathology, Coimbatore Medical College and Hospital, Coimbatore under the guidance and supervision of Dr.M.KAVITHA, M.D., Senior Assistant Professor, Department of Pathology, Coimbatore Medical College and Hospital, Coimbatore in partial fulfillment of the regulations of The Tamilnadu Dr.M.G.R Medical University, Chennai towards the award of degree of M.D.PATHOLOGY. Guide Dr. M.KAVITHA, M.D., Dr. A.DHANALAKSHMI, M.D., Senior Assistant Professor, Professor & Head, Department of Pathology, Department of Pathology, Coimbatore Medical College, Coimbatore Medical College, Coimbatore. Coimbatore . Dr. B.ASOKAN, M.S, M.Ch., Dean, Coimbatore Medical College, Coimbatore. CERTIFICATE –II This is to certify that this dissertation work titled “CYTOLOGIC SPECTRUM OF SALIVARY GLAND LESIONS WITH HISTOPATHOLOGICAL CORRELATION” of the candidate Dr.T.ANITHA with registration number 201713251 for the award of M.D degree in the branch of PATHOLOGY. I personally verified the urkund.com website for the purpose of plagiarism check I found that the uploaded thesis file contains from introduction to conclusion pages and result shows 7 (Seven) percentage of plagiarism in the dissertation. Guide and Supervisor sign with seal ACKNOWLEDGEMENT To begin with I thank the almighty God for bestowing his blessing on me in this dissertation a successful one. I wish to thank the dean Dr ASHOKAN, MS., Mch., Coimbatore Medical College and Hospital, for permitting me to conduct the study. It’s a great pleasure to express my humble gratitude to the most respectable teacher Dr .A. Dhanalakshmi MD., Professor and Head of the Department, Department of Pathology, Coimbatore Medical College, Coimbatore for her guidance and support. I express my gratitude and sincere thanks to my guide Dr.M.Kavitha M.D., Department of Pathology, Coimbatore Medical College, Coimbatore. I thank all Assistant Professors and Tutors of Department of Pathology, Coimbatore Medical College for their opinion and encouragement. I thank my parents, my children Srinidhi and Harshan, my friend Dr.Swathi for their extensive support. CONTENTS TABLE OF CONTENTS S.NO TITLE PAGE.NO 1 INTRODUCTION 1 2 AIM AND OBJECTIVES 4 3 REVIEW OF LITERATURE 5 4 MATERIALS AND METHODS 46 5 OBSERVATION AND RESULTS 49 6 DISCUSSION 71 7 SUMMARY 79 8 CONCLUSION 80 BIBLIOGRAPHY ANNEXURES MASTERCHART LIST OF TABLES S.NO TITLE PAGE.NO Age wise distribution of lesions of salivary 1 49 gland Gender wise distribution of lesions of salivary 2 51 gland Distribution of cases based on clinical 3 52 diagnosis Distribution of cases based on duration of 4 53 lesion 5 Distribution of cases based on size of lesion 55 6 Distribution of cases based on consistency 56 Distribution of cases based on location of 7 57 lesion Distribution of neoplastic tumors according to 8 58 histopathological diagnosis and location 9 Distribution of cases based on cellularity 59 10 Cytological diagnosis of salivary gland lesions 60 11 Cytological categorization of lesions 62 12 Histopathological diagnosis of lesion 63 13 Histopathological categorization of lesion 65 14 Cytohistopatholgical correlation 66 Diagnostic accuracy in benign neoplastic 15 67 lesions of salivary gland Diagnostic accuracy in malignant neoplastic 16 68 lesions of salivary gland Comparison of consistency –Benign Vs 17 69 Malignant Comparison of site of lesion-Benign Vs 18 70 Malignant Comparison of cellularity – Benign Vs 19 70 Malignant LIST OF CHARTS S.NO CHART PAGENO 1 Distribution of cases based on age 50 groups 2 Gender wise distribution of cases 51 3 Distribution of cases based on clinical 52 diagnosis 4 Distribution of case based on duration 54 of lesions 5 Distribution of cases based on size of 55 lesion 6 Distribution of cases based on 56 consistency 7 Distribution of cases based on location 57 of lesion 8 Distribution of cases based on 59 cellularity 9 Distribution of cases based on 61 Cytologic diagnosis 10 Distribution of cases based on 64 histopathological diagnosis ABBREVIATION FNAC - Fine needle aspiration cytology PA – Pleomorphic adenoma WT – Warthin’s tumor MEC – Mucoepidermoid Carcinoma CH SA – Chronic sialadenitis SD CA – Salivary duct carcinoma H &E – Hematoxylin and Eosin MGG – May GrunwaldGiemsa HPE –Histopathology Examination WHO - World Health Organisation INTRODUCTION INTRODUCTION Salivary glands are exocrine organs that secrete saliva widely distributed throughout the mouth and oropharynx. There are three pairs of salivary glands-parotid, submandibular and sublingual glands15. Minor salivary glands are about 800-100 located throughout the oral cavity in the buccal, labial lingual mucosa ,the soft palate ,lateral parts of hard palate and the floor of mouth. Salivary gland lesions form 2-5 percent of all Head and neck neoplasms4,6,8. Age incidence varies widely, extending from children to adults over 80 years of age. These glands are usually not subjected to incisional or core needle biopsy, because of the possible risk of fistula formation and tumor seedling18. Cysts and associated lesions with cystic changes are commonly encountered in Head and neck region. Pathology of these lesions are diverse and includes developmental, inflammatory, benign and malignant tumors which can be primary or metastatic. FNAC is a useful method for evaluating salivary gland lesions. It is of particular relevance in the head and neck area because of easy accessibility of the target site6 minimally invasive procedure, excellent patient compliance and thereby help to avoid surgery in non-neoplastic, inflammatory conditions. 1 It is a preferred method due to its low cost, rapid turnaround time, minimum morbidity. It has a high sensitivity and specificity for diagnosing neoplastic and non-neoplastic lesions It is useful to categorize the lesions into inflammatory, reactive, benign and malignant lesions and thereby useful for appropriate therapeutic management6,8,10. However, the heterogenecity of many salivary gland tumors along with overlap of cytomorphological features presents as a challenging work to conclude with precise diagnosis in some instances. The purpose of FNAC is not only to provide a definite specific diagnosis. But it is also used in conjunction with clinical and radiological findings to provide the best possible initial assessment from which management can be planned1,10. Till date, ultrasonography is acting as bridge between surgery and pathology.17 Pre-operative assessment of parotid swelling by cytology and ultrasonography is especially significant in our country where tuberculosis and metastatic squamous cell carcinoma invading perisalivary lymph nodes mimic parotid swelling. Major salivary gland neoplasms usually present with non-specific clinical symptoms ,requiring high degree of suspicion. FNAC offers an invaluable and accurate initial diagnostic tool for the management of these patients even in the era of the Immunohistochemistry. 2 The present study aims to correlate cytomorphological features of salivary gland lesions in FNAC and the corresponding histopathology in suspicious malignant cases. Keeping histopathological diagnosis as gold standard sensitivity, specificity and diagnostic accuracy of FNAC was calculated. An adequate and representative sampling is essential for proper cytological evaluation to reduce the errors in diagnosis. The diagnostic pitfalls in FNAC were evaluated along with practical suggestions to improve the diagnostic accuracy especially while dealing with mucinous lesions. Other varied reasons for diagnostic errors may be due to uncertainty of the site and tissues aspirated , minimal material and lack of architectural pattern in the smears as compared to histological sections. Relevant clinical data, radiological findings, along with cooperation between the clinician and cytopathologist10,13 are important in order to use FNAC to its best advantage. Thus the present study offers to examine the sensitivity, specificity and diagnostic accuracy of FNAC of salivary gland lesions with histopathological correlation and to identify the discrepancies contributing to pitfalls in diagnosis. 3 AIM & OBJECTIVES AIMS AND OBJECTIVES AIM: To analyse the diagnostic accuracy, sensitivity and specificity of FNAC in various salivary gland lesions and correlate with the histopathological findings. OBJECTIVES: 1. To analyse the clinical, Histological and cytological features of salivary gland
Recommended publications
  • Basal Cell Adenoma of Zygomatic Salivary Gland in a Young Dog – First Case Report in Mozambique

    Basal Cell Adenoma of Zygomatic Salivary Gland in a Young Dog – First Case Report in Mozambique

    RPCV (2015) 110 (595-596) 229-232 Basal cell adenoma of zygomatic salivary gland in a young dog – First case report in Mozambique Adenoma das células basais da glândula salivar zigomática em cão jovem – Primeiro relato de caso em Moçambique Ivan F. Charas dos Santos*1,2, José M.M. Cardoso1, Giovanna C. Brombini3 Bruna Brancalion3 1Departamento de Cirurgia, Faculdade de Veterinária, Universidade Eduardo Mondlane, Maputo, Moçambique 2Pós-doutorando (Bolsista FAPESP), Departamento de Cirurgia e Anestesiologia Veterinária, Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brasil. 3Faculdade de Medicina Veterinária e Zootecnia (FMVZ), Universidade Estadual Paulista (UNESP),Botucatu, São Paulo, Brasil. Summary: Basal cell adenoma of zygomatic salivary gland Introduction was described in a 1.2 years old Rottweiler dog with swelling of right zygomatic region tissue. Clinical signs were related to Salivary glands diseases in small animals include anorexia, slight pain on either opening of the mouth. Complete blood count, serum biochemistry, urinalysis, thoracic radio- mucocele, salivary gland fistula, sialadenitis, sialad- graphic examination; and transabdominal ultrasound showed enosis, sialolithiasis and less neoplasia (Spangler and no alteration. The findings of cytology examination were con- Culbertson, 1991; Johnson, 2008). Primary tumours sistent with benign tumour and surgical treatment was elected. of salivary glands are rare in dogs and not common- The histopathologic examinations were consistent with basal ly reported in small animals. The incidence is about cell adenoma of zygomatic salivary gland. Seven days after the surgery no alteration was observed. One year later, the dog re- 0.17% in dogs with age between 10 and 12 years turned to check up and confirmed that the dog was healthy and old (Spangler and Culbertson, 1991; Hammer et al., free of clinical and laboratorial signs of tumour recurrence or 2001; Head and Else, 2002).
  • Diseases of Salivary Glands: Review

    Diseases of Salivary Glands: Review

    ISSN: 1812–1217 Diseases of Salivary Glands: Review Alhan D Al-Moula Department of Dental Basic Science BDS, MSc (Assist Lect) College of Dentistry, University of Mosul اخلﻻضة امخجوًف امفموي تُئة رطبة، حتخوي ػىل طبلة ركِلة من امسائل ثدغى انوؼاب ثغطي امسطوح ادلاخوَة و متﻷ امفراغات تني ااطَة امفموًة و اﻷس نان. انوؼاب سائل مؼلد، ًنذج من امغدد انوؼاتَة، اذلي ًوؼة دورا" ىاما" يف اﶈافظة ػىل سﻻمة امفم. املرىض اذلٍن ؼًاهون من هلص يف اﻷفراز انوؼايب حكون دلهيم مشبلك يف اﻷلك، امخحدث، و امبوع و ًطبحون غرضة مﻷههتاابت يف اﻷغش َة ااطَة و امنخر املندرش يف اﻷس نان. ًوخد ثﻻثة أزواج من امغدد انوؼاتَة ام ئرُسة – امغدة امنكفِة، امغدة حتت امفكِة، و حتت انوساهَة، موضؼيا ٍكون خارج امخجوًف امفموي، يف حمفظة و ميخد هظاهما املنَوي مَفرغ افرازاهتا. وًوخد أًضا" امؼدًد من امغدد انوؼاتَة امطغرية ، انوساهَة، اتحنكِة، ادلىوزيًة، انوساهَة احلنكِة وما كبل امرخوًة، ٍكون موضؼيا مﻷسفل و مضن امغشاء ااطي، غري حماطة مبحفظة مع هجاز كنَوي كطري. افرازات امغدد انوؼاتَة ام ئرُسة مُست مدشاهبة. امغدة امفكِة ثفرز مؼاب مطيل غين ابﻷمِﻻز، وامغدة حتت امفكِة ثنذج مؼاب غين اباط، أما امغدة حتت انوساهَة ثنذج مؼااب" مزخا". ثبؼا" ميذه اﻷخذﻻفات، انوؼاب املوحود يق امفم ٌشار امَو مكزجي. ح كرَة املزجي انوؼايب مُس ثس َطا" واملادة اﻷضافِة اموػة من لك املفرزات انوؼاتَة، اكمؼدًد من امربوثُنات ثنذلل ثرسػة وثوخطق هبدروكس َل اﻷتُذاًت مﻷس نان و سطوح ااطَة امفموًة. ثبدأ أمراض امغدد انوؼاتَة ػادة تخغريات اندرة يف املفرزات و ام كرتَة، وىذه امخغريات ثؤثر اثهواي" من خﻻل جشلك انووحية اجلرثومِة و املوح، اميت تدورىا ثؤدي اىل خنور مذفش َة وأمراض وس َج دامعة. ىذه اﻷمراض ميكن أن ثطبح شدًدة تؼد املؼاجلة امشؼاغَة ﻷن امؼدًد من احلاﻻت اجليازًة )مثل امسكري، امخوَف اهكُيس( ثؤثر يف اجلراين انوؼايب، و ٌش خيك املرض من حفاف يف امفم.
  • ICD-9 Diagnosis Codes Effective 10/1/2011 (V29.0) Source: Centers for Medicare and Medicaid Services

    ICD-9 Diagnosis Codes Effective 10/1/2011 (V29.0) Source: Centers for Medicare and Medicaid Services

    ICD-9 Diagnosis Codes effective 10/1/2011 (v29.0) Source: Centers for Medicare and Medicaid Services 0010 Cholera d/t vib cholerae 00801 Int inf e coli entrpath 01086 Prim prg TB NEC-oth test 0011 Cholera d/t vib el tor 00802 Int inf e coli entrtoxgn 01090 Primary TB NOS-unspec 0019 Cholera NOS 00803 Int inf e coli entrnvsv 01091 Primary TB NOS-no exam 0020 Typhoid fever 00804 Int inf e coli entrhmrg 01092 Primary TB NOS-exam unkn 0021 Paratyphoid fever a 00809 Int inf e coli spcf NEC 01093 Primary TB NOS-micro dx 0022 Paratyphoid fever b 0081 Arizona enteritis 01094 Primary TB NOS-cult dx 0023 Paratyphoid fever c 0082 Aerobacter enteritis 01095 Primary TB NOS-histo dx 0029 Paratyphoid fever NOS 0083 Proteus enteritis 01096 Primary TB NOS-oth test 0030 Salmonella enteritis 00841 Staphylococc enteritis 01100 TB lung infiltr-unspec 0031 Salmonella septicemia 00842 Pseudomonas enteritis 01101 TB lung infiltr-no exam 00320 Local salmonella inf NOS 00843 Int infec campylobacter 01102 TB lung infiltr-exm unkn 00321 Salmonella meningitis 00844 Int inf yrsnia entrcltca 01103 TB lung infiltr-micro dx 00322 Salmonella pneumonia 00845 Int inf clstrdium dfcile 01104 TB lung infiltr-cult dx 00323 Salmonella arthritis 00846 Intes infec oth anerobes 01105 TB lung infiltr-histo dx 00324 Salmonella osteomyelitis 00847 Int inf oth grm neg bctr 01106 TB lung infiltr-oth test 00329 Local salmonella inf NEC 00849 Bacterial enteritis NEC 01110 TB lung nodular-unspec 0038 Salmonella infection NEC 0085 Bacterial enteritis NOS 01111 TB lung nodular-no exam 0039
  • Statistical Analysis Plan

    Statistical Analysis Plan

    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
  • Salivary Gland Pathology 25.Pdf

    Salivary Gland Pathology 25.Pdf

    k Index 461 Mechanoreceptors, 15 patient history, 284 Melanoma pleomorphic adenoma, 286–290 desmoplastic subtype, 63 polymorphous low-grade adenocarcinoma, 174–175, 306, histopathology, 381 309, 312 lower lip, 380–381 primary lymphomas, 368 metastases, 62–63, 189 radiation therapy, 328 nodular, 379 sites of, 285 Merkel cell tumors, metastases, 62, 63, 375 staging, 193–196 Mesenchymal-epithelial transition (MET), 214 Mixed tumor. See Pleomorphic adenoma(s) Mesenchymal neoplasms, 188 Modified Blair incision, 238, 239 Mesenchymal salivary gland tumors Monomorphic adenoma, 167–169, 290 lymphatic malformations, 398, 400 Monomorphic clear cell tumor, 182 neural tumors, 398, 401, 402 Motion artifacts, 21–22 vascular tumors, 397–398, 397–399 Mouth Messenger ribonucleic acid (mRNA), 208, 209, 209 dry, 141 Metal deposits, brain, 24 ranula, 98, 99, 100 Metallic implants, 21, 22 MRI. See Magnetic resonance imaging (MRI) Metalloproteinases, 142 MRS. See Magnetic resonance spectroscopy (MRS) Metastases, 189 Mucocele, 97, 99, 114, 412 diagnostic imaging, 62–64, 63 Mucoepidermoid carcinoma (MEC), 170–172, 214, 389, distant. See Distant metastases 390, 396, 404 regional. See Regional metastases ADC values, 27 skip, 270 biomarkers, 190, 263 Metastasizing mixed tumor, 182, 289 buccal mucosa, 294 Metastasizing pleomorphic adenoma, 287 children, 297 Methicillin resistant S. aureus (MRSA), acute bacterial clear cell variant, 383 parotitis, 75, 78, 96 diagnostic imaging, 56, 57 k Microliths, 439 fixed to mandible, 277 k Middle ear, aberrant glands, 438 grading,
  • 1 Surgical Pathology of the Mouth and Jaws R. A. Cawson, J. D. Langdon

    1 Surgical Pathology of the Mouth and Jaws R. A. Cawson, J. D. Langdon

    Surgical pathology of the mouth and jaws R. A. Cawson, J. D. Langdon, J. W. Eveson 12. Tumours of salivary glands A great variety of neoplasms can form in the salivary gland tissues. The classification of Thackray and Sobin (1972) (Table 12.1) is still widely used, but inevitably has been overtaken by the recognition of new types of tumours. A modified classification broadly based on changes proposed by the WHO Collaborating Center for Salivary Gland Tumors is therefore shown in Table 12.2, but even so it is not always easy to fit a particular tumour into one of these many categories. Non-neoplastic diseases have been discussed in the previous chapter, but in the parotid gland particularly it is not always possible to distinguish them from neoplasms preoperatively. Table 12.1 Classification of salivary gland tumours (After Thackray and Sobin, 1972) Epithelial A. Adenomas 1. Pleomorphic adenoma (mixed tumour) 2. Monomorphic adenoma (a) Adenolymphoma (Warthin's tumour) (b) Oxyphilic adenoma (oncocytoma) (c) Other monomorphic adenomas B. Mucoepidermoid tumour C. Acinic cell tumour D. Carcinomas 1. Adenoid cystic carcinoma 2. Adenocarcinoma 3. Squamous cell carcinoma 4. Undifferentiated carcinomas 5. Carcinoma in pleomorphic adenoma Non-Epithelial Haemangioma Lymphangioma Neurofibroma Lipoma Others including malignant varieties of the above Lymphoma. Age, site and sex distribution in relatin to tumour type In the British Salivary Gland Tumour Panel series of more than 3500 unselected tumours, there is a wide age distribution, but the peak incidence for benign tumours is in the sixth decade and, for malignant tumours, the seventh. Thus in the third decade, nearly 95% of tumours are benign, but by the seventh decade and after, 30% of tumours are malignant.
  • Description Concept ID Synonyms Definition

    Description Concept ID Synonyms Definition

    Description Concept ID Synonyms Definition Category ABNORMALITIES OF TEETH 426390 Subcategory Cementum Defect 399115 Cementum aplasia 346218 Absence or paucity of cellular cementum (seen in hypophosphatasia) Cementum hypoplasia 180000 Hypocementosis Disturbance in structure of cementum, often seen in Juvenile periodontitis Florid cemento-osseous dysplasia 958771 Familial multiple cementoma; Florid osseous dysplasia Diffuse, multifocal cementosseous dysplasia Hypercementosis (Cementation 901056 Cementation hyperplasia; Cementosis; Cementum An idiopathic, non-neoplastic condition characterized by the excessive hyperplasia) hyperplasia buildup of normal cementum (calcified tissue) on the roots of one or more teeth Hypophosphatasia 976620 Hypophosphatasia mild; Phosphoethanol-aminuria Cementum defect; Autosomal recessive hereditary disease characterized by deficiency of alkaline phosphatase Odontohypophosphatasia 976622 Hypophosphatasia in which dental findings are the predominant manifestations of the disease Pulp sclerosis 179199 Dentin sclerosis Dentinal reaction to aging OR mild irritation Subcategory Dentin Defect 515523 Dentinogenesis imperfecta (Shell Teeth) 856459 Dentin, Hereditary Opalescent; Shell Teeth Dentin Defect; Autosomal dominant genetic disorder of tooth development Dentinogenesis Imperfecta - Shield I 977473 Dentin, Hereditary Opalescent; Shell Teeth Dentin Defect; Autosomal dominant genetic disorder of tooth development Dentinogenesis Imperfecta - Shield II 976722 Dentin, Hereditary Opalescent; Shell Teeth Dentin Defect;
  • Toma, 539 Acinic Cell Carcinoma Mucinous Adenocarcinoma Vs., 334

    Toma, 539 Acinic Cell Carcinoma Mucinous Adenocarcinoma Vs., 334

    Cambridge University Press 978-0-521-87999-6 - Head and Neck Margaret Brandwein-Gensler Index More information INDEX acanthomatous/desmoplastic ameloblas- ameloblastomas benign neoplasia toma, 539 desmoplastic ameloblastoma, 539 juvenile nasopharyngeal angiofibroma, acinic cell carcinoma metastasizing ameloblastoma, 537 99–104 mucinous adenocarcinoma vs., 334–335 mural ameloblastoma, 533 salivary gland anlage tumor, 104–106 oncocytoma vs., 295–299 odonto-ameloblastoma, 551–553 benign peripheral nerve sheath tumors papillary cystic variant, vs. cystade- peripheral ameloblastoma, 534 (BPNST), 40–44 noma, 316–317 unicystic ameloblastoma, 532–533 benign sinonasal tract neoplasia, 28–48 salivary glands, 353–359 aneurysmal bone cyst (ABC), 584 benign peripheral nerve sheath tumor, adenocarcinoma not otherwise specified central GCRG vs., 590–591 40–44 (ANOS), 389–390 angiocentric T-cell lymphoma, 81 meningioma, 37–40 adenoid cystic carcinoma (ACC) angiomatoid/angioectatic polyps vs. JNAF, nasal glial heterotopia (NGH), 44–48 adenomatoid odontogenic tumor vs., 100–104 oncocytic Schneiderian papilloma 545 angiosarcoma vs. Kaposi’s sarcoma, 206 (OSP), 5, 33–36 basal cell adenocarcinoma vs., 372 antrochoanal polyp, 5–8 Schneiderian inverted papilloma, 28–32 basal cell adenoma vs., 293 apical periodontal cyst, 510–512 bisphosphonate osteonecrosis (BPP), canalicular adenoma vs., 294 arytenoid chondrosarcomas, 241 565–566 neuroendocrine carcinoma vs., 240–241 atrophic oral lichen planus, 126 blastomas of salivary glands, 319–325 atypical adenoma vs. parathyroid
  • Sialoblastoma of the Cheek: a Case Report and Review of the Literature

    Sialoblastoma of the Cheek: a Case Report and Review of the Literature

    MOLECULAR AND CLINICAL ONCOLOGY 4: 925-928, 2016 Sialoblastoma of the cheek: A case report and review of the literature PEERAYUT SITTHICHAIYAKUL1, JULINTORN SOMRAN1, NONGLUK OILMUNGMOOL2, SARAN WORASAKWUTTIPONG3 and NOPPADOL LARBCHAROENSUB4 Departments of 1Pathology, 2Radiology and 3Surgery, Faculty of Medicine, Naresuan University, Phitsanulok 65000; 4Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand Received November 23, 2015; Accepted March 21, 2016 DOI: 10.3892/mco.2016.840 Abstract. Sialoblastoma is a rare salivary gland tumor that basal cell adenoma, basaloid adenocarcinoma, congenital hybrid recapitulates the primitive salivary gland anlage. The authors basal cell adenoma-adenoid cystic carcinoma, and embryoma. herein report a case of sialoblastoma of a minor salivary gland, Sialoblastoma most commonly affects the major salivary glands clinically presenting with progressive enlargement of a mass and is histologically characterized by variably arranged, tight in the cheek of a 1-year-old female infant. Histopathologically, clusters or clumps of basaloid cells and partially formed ductal the mass consisted of tight clusters of basaloid cells and and pseudo‑ductal spaces separated by thin fibrous bands. The partially formed ductal and pseudo-ductal spaces separated overall prognosis of this type of tumor remains controversial. by thin fibrous bands. Immunohistchemical studies demon- Sialoblastoma has a tendency to progress to local invasion, local strated the presence of cytokeratin AE1̸AE3, p63, CD99, recurrence and occasional metastasis. In 1996, according to the α-fetoprotein (AFP) and Hep Par-1 expression in a considerable third series of the Armed Forces Institute of Pathology (AFIP) number of tumor cells. The clinical and pathological charac- classification of salivary gland tumors, sialoblastoma was clas- teristics are presented and relevant literature is reviewed.
  • 20 Diagnosis and Management of Salivary Gland Disorders

    20 Diagnosis and Management of Salivary Gland Disorders

    Diagnosis and Management of Salivary Gland Disorders Michael Miloro and Sterling R. Schow CHAPTER CHAPTER OUTLINE EMBRYOLOGY, ANATOMY, AND PHYSIOLOGY OBSTRUCTIVE SALIVARY GLAND DISEASE DIAGNOSTIC MODALITIES Sialolithiasis History and Clinical Examination Salivary Gland MUCOUS RETENTION AND EXTRAVASATION Radiology Plain Film Radiographs Sialography PHENOMENA Computed Tomography, Magnetic Resonance Mucocele Imaging, and Ultrasound Ranula Salivary Scintigraphy (Radioactive Isotope SALIVARY GLAND INFECTIONS Scanning) NECROTIZING SIALOMETAPLASIA SJOGREN'S SYNDROME Salivary Gland Endoscopy (Sialoendoscopy) TRAUMATIC SALIVARY GLAND INJURIES Sialochernistry NEOPLASTIC SALIVARY GLAND DISORDERS Fine-Needle Aspiration Biopsy Benign Salivary Gland Tumors Salivary Gland Biopsy Malignant Salivary Gland Tumors he clinician is frequently confronted with EMBRYOLOGY, ANATOMY, AND PHYSIOLOG the necessity of assessing and The salivary glands can be divided into two groups: managing salivary gland disorders. A the minor and major glands. All salivary glands develop thorough knowledge of the embryology, anatomy, and from the embryonic oral cavity as buds of pathophysiology is necessary to treat patients epithelium that extend into the underlying appropriately. This chapter examines the cause, mesenchymal tissues. The epithelial ingrowths diagnostic methodology, radiographic evaluation, and branch to form a primitive ductal system that management of a variety of salivary gland disorders, eventually becomes canalized to provide for drainage including sialolithiasis and obstructive phenomena of salivary secretions. The minor salivary glands begin (e.g., mucocele and ranula), acute and chronic to develop around the fortieth day in utero, where- as salivary gland infections, traumatic salivary gland the larger major glands begin to develop slightly earli- disorders, S]6gren's syndrome (SS), necrotizing er, at about the thirty-fifth day in utero. At around sialometaplasia, and benign and malignant salivary the seventh or eighth month in utero, secretory cells gland tumors.
  • The Effect of Botulinum Toxin on an Iatrogenic Sialo-Cutaneous Fistula

    The Effect of Botulinum Toxin on an Iatrogenic Sialo-Cutaneous Fistula

    Arch Craniofac Surg Vol.17 No.4, 237-239 Archives of Cr aniofacial Surgery https://doi.org/10.7181/acfs.2016.17.4.237 The Effect of Botulinum Toxin on an Iatrogenic Sialo-Cutaneous Fistula Seung Eun Hong, A sialo-cutaneous fistula is a communication between the skin and a salivary gland or duct Jung Woo Kwon, discharging saliva. Trauma and iatrogenic complications are the most common causes So Ra Kang, of this condition. Treatments include aspiration, compression, and the administration of Bo Young Park systemic anticholinergics; however, their effects are transient and unsatisfactory in most cases. We had a case of a patient who developed an iatrogenic sialo-cutaneous fistula Department of Plastic and Reconstructive after wide excision of squamous cell carcinoma in the parotid region that was not treated Surgery, Ewha Womans University Mokdong Case Report Hospital, Ewha Womans University School of with conventional management, but instead completely resolved with the injection of Medicine, Seoul, Korea botulinum toxin. Based on our experience, we recommend the injection of botulinum toxin into the salivary glands, especially the parotid gland, as a conservative treatment option for sialo-cutaneous fistula. No potential conflict of interest relevant to Keywords: Salivary gland fistula / Botulinum toxins / Squamous cell carcinoma this article was reported. INTRODUCTION vasive, stressful, and lengthy than conventional methods. We re- port a case in which an iatrogenic sialo-cutaneous fistula in the A sialo-cutaneous fistula is defined as a communication between preauricular area after skin cancer removal was successfully treat- the skin and a salivary gland resulting in the discharge of saliva ed with the injection of type A botulinum toxin.
  • Sialoblastoma of the Sublingual Gland: a Case Report

    Sialoblastoma of the Sublingual Gland: a Case Report

    Central Journal of Ear, Nose and Throat Disorders Case Report *Corresponding author Ndongo Pilor, Clinique d’ORL et de Chirurgie cervico-faciale, CHU de Fann, Dakar, Sénégal, Tel : Sialoblastoma of the Sublingual 00221775635500; Email: [email protected] Submitted: 06 January 2020 Accepted: 18 January 2020 Gland: A Case Report Published: 20 January 2020 ISSN: 2475-9473 Ndongo Pilor1*, Ciré Ndiaye1, Mame Sanou DIOUF2, Houra Copyright 1 1 Ahmed , and Issa Cheikh NDIAYE © 2020 Pilor N, et al. 1Clinique d’ORL et de Chirurgie cervico-faciale, CHU de Fann, Dakar – Sénégal OPEN ACCESS 2Clinique d’ORL et de chirurgie cervico-faciale, Centre Hospitalier Universitaire Idrissa Pouye de Grand Yoff, Dakar - Sénégal Keywords • Sialoblastoma Abstract • Congenital tumor • Salivary glands Introduction : Sialoblastoma is a rare, congenital malignant epithelial tumor of the • Sublingual gland salivary glands. It is located mainly in the parotid and maxillary glands. Its location in the sublingual gland is exceptional. Summary of the clinical case : We report the case of a 10-month-old infant, with no pathological history, who consulted for a congenital mass under left mandibular, gradually increasing in volume. The examination found a left submandibular mass of about 10 centimeters long axis, firm, mobile compared to the 2 planes, painless with a healthy skin. The cervical CT showed a left mandibular mass, tissue, with regular contours; without lymphadenopathy. The patient had a complete excision of the mass under general anesthesia. Intraoperatively, we found a mass of cerebral aspect extending forward and inward of the left maxillary gland which was normal in appearance. The postoperative course was simple.